BG45
CAS No. : 926259-99-6
| Size | Price | Stock |
|---|---|---|
| 5mg | $72 | In-stock |
| 10mg | $120 | In-stock |
| 50mg | $360 | In-stock |
| 100mg | $576 | In-stock |
| 200 mg | Get quote | |
| 500 mg | Get quote | |
| We match the lowest price on market. | ||
We offer a substantial discount on larger orders, please inquire via [email protected]
or Fax: (86)21-58955996
Inquiry for price and availability only. Please place your order via our email or fax.
| Cat. No. : | HY-18712 |
| M.Wt: | 214.22 |
| Formula: | C11H10N4O |
| Purity: | >98 % |
| Solubility: | DMSO : ≥ 48 mg/mL |
BG45 is a potent HDAC3 inhibitor with IC50 values of 0.289, 2, 2.2 and ﹥20 μM for HDAC3, HDAC1, HDAC2 and HDAC6, respectively. BG45 selectively targets multiple myeloma (MM) cells and induces caspase-dependent apoptosis[1][2].
In Vitro: BG45 (1.875-30 µM; 48 and 72 h) targets multiple myeloma (MM) cells and inhibits cell growth in a dose-dependent manner[1].
BG45 (15 µM; 0-48 h; MM.1S cells) induces apoptosis via caspase-3/PARP cleavage[1].
BG45 (10 and 20 µM; 12 h; MM.1S cells) induces acetylation of histone H2A, H3, and H4 in a dose-dependent manner[1].
BG45 (10 and 20 µM; 10 h; MM.1S cells) induces multiple myeloma (MM) cells toxicity is associated with hyperacetylation of histones and STAT3 and downregulation of p-STAT3[1].
In Vivo: BG45 (15-50 mg/kg; i.p.; 5 days a week for 3 weeks; CB17 SCID mice with MM.1S xenograft model) inhibits human multiple myeloma (MM) cells growth and enhances bortezomib (HY-10227) induced cytotoxicity in vivo[1].
Lorem ipsum dolor sit amet, consectetur adipisicing elit. Autem earum hic iste maiores, nam neque rem suscipit. Adipisci consequatur error exercitationem fugit ipsam optio qui, quibusdam repellendus sed vero! Debitis.
Inquiry Information- Product Name:
- BG45
- Cat. No.:
- HY-18712
- Quantity:
Your information is safe with us.